Pope Francis injured his right arm after suffering a fall earlier this week. According to the Vatican, while the 88-year-old pontiff did not break his arm, a sling was put on as a precaution. This incident comes just weeks after another fall on December 7, where he hit his chin on a nightstand, resulting in another, visible bruise. The pope's health has been a topic of ongoing speculation due to his age and medical history, which includes long bouts of bronchitis and mobility challenges. Often seen using a wheelchair or a cane, Francis also uses a walker within the Vatican's Santa Marta hotel, where he resides. Notably, his frailty has brought renewed attention to the risks of falls among elderly individuals and the steps one must follow to mitigate such falls.

Preventive Measures For Bone Health

A study published in Frontiers in Aging Neurosciences people get older, the bone density in the lower back and thigh bone decreases significantly. This raises the risk of osteoporosis (OP). Therefore it becomes pivotal to pay early attention to nutrition, exercise ability, vitamin D levels, and uric acid levels in older individuals to prevent Ostreopsis and mitigate fall risks. The risk of falls and bone injuries among elderly individuals underscores the importance of preventive measures for maintaining bone health and minimizing fall risks.

Elderly, particularly menopausal women, require a daily calcium intake of 1,200 mg, divided into two or more doses. This can be achieved through dietary sources such as dairy and non-dairy products or through supplements like calcium carbonate and calcium citrate. However, total daily calcium intake should not exceed 2,500 mg to avoid potential health risks.

Vitamin D is essential for calcium absorption and bone mineralization. While sunlight exposure helps synthesize vitamin D, older individuals often require supplements due to reduced skin synthesis and the limited availability of foods. Fortified milk and supplements containing 200–600 IU of vitamin D daily are recommended, with higher doses required for those with deficiencies. Severe cases may necessitate high-dose treatments, such as 50,000 IU weekly for up to three months, along with regular monitoring of calcium and vitamin D levels.

Regular exercise is vital for preserving bone mass and reducing fall risk. Weight-bearing activities, strength training, and balance exercises like brisk walking or skipping can enhance bone density and improve coordination. Experts recommend at least 30 minutes of moderate physical activity most days of the week, supplemented by strength training twice weekly. For individuals unable to engage in standard exercise routines, alternatives like vibrating platforms may help maintain bone health.

Falls remain a leading cause of fractures among individuals over 60. Addressing contributing factors such as balance issues, vision problems, and environmental hazards can significantly reduce risks. Preventive measures include regular vision checks, minimizing medications causing dizziness, improving home safety (e.g., installing railings and removing loose rugs), and wearing rubber-soled footwear. Hip protectors may also help mitigate the impact of falls.

Former British Olympic sprinter Beth Dobbin, diagnosed with myalgic encephalomyelitis (ME), spends more than 22 hours a day in bed because of the debilitating condition. She is urging UK Prime Minister Andy Burnham to meet her and commit to increased government funding for ME research.

Following Dobbin's October 21 appeal, 360 sportspeople have signed a letter backing her campaign. The group includes 114 Olympians and Paralympians, who have won a combined 77 medals.

In a post on X, Dobbin expressed surprise at the response, saying: “I can’t believe 360 people signed in just 1 week, so many amazing names and messages still coming in of people wanting to add theirs (so feel free to message to add yours, we’re keeping on the pressure!!!)”

The 32-year-old retired from athletics in April 2026, describing her illness as “serious” and “life-changing”, BBC Sport reported. She had reached the 200m semi-finals at the Tokyo Olympics in 2021 and won bronze in the 4x200m relay with Scotland at the 2022 Commonwealth Games in Birmingham.

360 Sportspeople Back Beth Dobbin's Call For ME Research Funding

Also read: Swimmer Archie Goodburn’s Plea Prompts UK Brain Cancer Research Review

Among the signatories are Everton manager David Moyes, United States women's national football team manager Emma Hayes, former Chelsea and England centre-back Millie Bright, athletes Laura Muir, Eilish McColgan and Adam Gemili, Olympic sprinter Dina Asher-Smith and diver Tom Daley.

The letter calls on Burnham to “level the playing field” for ME research funding compared with other illnesses and “give hope to the many affected that something is being done about this life-destroying, much-ignored illness and its spiralling impact”.

It highlights the disparity in government research funding between ME and other conditions.

“Between 2019 to 2024, UK government research funders committed just £6.6m in funding for research into ME, compared to £79.1m for Parkinson's and £496.4m for dementia,” the letter states.

It adds that biomedical research funding for ME was “almost non-existent” before this period and that the lack of investment has contributed to the absence of approved treatments.

How Did Beth Dobbin Develop ME?

Dobbin's health began deteriorating after back-to-back COVID-19 and glandular fever infections during the winter of 2021-22, she told BBC Sport.

She experienced worsening fatigue, slower running times and soreness in the glands in her neck and armpits. Initial tests by British Athletics doctors failed to identify the cause.

Despite her symptoms, she continued training in 2022. At the European Championships, she false-started after losing all feeling in her legs while in the starting blocks.

Her condition continued to worsen. She struggled to stand and spent most of her time in bed. After consulting four or five specialists, she was diagnosed with ME.

Dobbin has since been largely confined to her home and bed. Even conversations, bright lights and loud sounds can trigger a “crash” lasting days or, in severe cases, months. According to BBC Sport, she has left her house just five times this year, mainly for medical appointments and blood tests.

Read More: Spanish Striker Jesus De Miguel Dies After On-Field Collision: Can A Blow To The Chest Trigger Cardiac Arrest?

What Is Myalgic Encephalomyelitis (ME)?

ME, also known as chronic fatigue syndrome (CFS), is a complex, chronic illness that can cause severe fatigue, pain, sleep disturbances and problems with thinking and memory.

Symptoms do not improve with rest and can fluctuate in severity. While some people can continue working or studying, others experience severe disability and may require round-the-clock care or tube feeding.

There is no known cure or specific approved treatment for ME. More than 400,000 people in the UK are thought to have the condition, although the actual number could exceed one million.

A Department of Health and Social Care spokesperson previously told BBC Sport: “Myalgic encephalomyelitis (ME) can have a devastating impact on people's lives, and we are determined to accelerate progress in understanding and treating this debilitating condition.”

The 2026 US midterm elections have delivered significant victories for Democrats, including two healthcare professionals. Physician Amy Acton defeated Republican Vivek Ramaswamy in Ohio’s gubernatorial race, while paediatrician Annie Andrews won South Carolina’s Senate race against Republican Darline Graham.

Both victories have brought healthcare professionals into the political spotlight as medical costs, insurance affordability and access to treatment remain major concerns for American voters.

Acton, a former director of the Ohio Department of Health, became widely recognised for her leadership during the COVID-19 pandemic. Andrews drew on her experience as a paediatrician to campaign on healthcare access and affordability.

"It’s the honor of my lifetime to be named your Ohio Governor-Elect," Acton said, in an Instagram post.

"South Carolina, you have shown the nation — in an era of partisan divides, of vitriol and namecalling, in a politics dominated by billionaires, special interests, and insiders in Washington — that we will not bow down. We will not back down. And we will chart our own course," added Andrews on X.

Democrats Make Major Gains In US Midterm Elections

Also read: US Midterms 2026: 125 Doctors, Nurses And Health Experts Join Election Battle

Acton's victory marks a setback for Republicans in Ohio, where the governor's office was previously held by the party. She sought to return the governorship to Democrats after two decades, despite Ohio's increasingly Republican lean in recent elections.

The closely watched contest saw Ramaswamy, a biotech entrepreneur and former 2024 Republican presidential candidate, secure the Republican nomination with endorsements from President Donald Trump and the state Republican Party.

According to the Associated Press (AP), Acton received 50.8% of the vote, against Ramaswamy's 45.9%, with 86% of ballots counted.

In South Carolina, Andrews defeated Darline Graham, the sister of the late Republican Senator Lindsey Graham. She became the first Democrat to win a US Senate seat in the state in 28 years.

What Could These Wins Mean For Healthcare Policy?

The Democratic gains could create opportunities to challenge President Donald Trump's healthcare agenda through congressional oversight and legislative action.

Healthcare affordability was a major voter concern. A Kaiser Family Foundation (KFF) poll found that six in 10 registered voters worried about medical costs. Voters trusted Democrats more than Republicans on healthcare costs (42% versus 22%) and abortion policy (42% versus 27%).

Abortion-related measures also featured on ballots in Virginia, Nevada, Idaho and Missouri, where voters considered repealing existing abortion protections.

Read More: US Midterm Elections 2026: Abortion, Medicaid, Measles And Healthcare Issues At Stake

What Did Annie Andrews And Amy Acton Promise On Healthcare?

Both candidates used their medical backgrounds to build campaigns around reducing healthcare costs, protecting patients and expanding access to treatment.

Annie Andrews' healthcare promises

The paediatrician campaigned on a 'Patients and Prices Platform'. Her key promises included:

• Lower drug prices: Expand Medicare drug price negotiations and restructure insurance rules to limit corporate profits.
• Public option: Introduce voluntary public health insurance instead of Medicare for All.
• Protect Medicaid: Reverse federal Medicaid cuts and safeguard rural hospitals.
• Public health: Expand vaccine access and strengthen maternal health services.
• Reproductive rights: Restore federal abortion protections and safeguard access to contraception and fertility treatments, including IVF.

Amy Acton's healthcare promises

The former Ohio health director focused on reducing medical debt, protecting Medicaid coverage and strengthening hospitals. Her key promises included:

• Medical debt relief: Eliminate medical debt for eligible residents earning up to 400% of the federal poverty level or whose medical debt exceeded 5% of household income.
• Lower medication costs: Launch 'Ohio Rx', a state-run online pharmaceutical platform to reduce drug prices through collective purchasing.
• Protect Medicaid: Oppose coverage cuts and establish navigator programmes to help residents retain insurance.
• Support hospitals: Provide funding to vulnerable rural and urban safety-net hospitals.
• Patient protections: Address surprise medical bills, improve insurance price transparency and prevent mid-plan medication switches.
• Reproductive rights: Defend Ohio's reproductive freedom amendment and protect access to abortion, contraception, IVF and miscarriage care.

The UK's National Health Service (NHS) is launching a major trial of blood tests designed to detect 13 different cancers, including bowel, pancreatic, liver and ovarian cancer.

More than 20,000 patients with symptoms like constant bloating or abdominal discomfort are invited to participate in the trial. It spans across more than 200 GP practices in England.

Called STRIDE-RCT, the study is being led by the University of Birmingham and will assess whether three different blood tests can help GPs identify patients who may need further cancer screening sooner.

The tests detect either tiny fragments of DNA released by tumours into the bloodstream or proteins linked with the body's response to cancer.

A single blood sample could provide signals linked with several cancer types and help indicate where the cancer may have originated.

The trial is aimed to determine if certain cancers can be detected early, especially those whose symptoms may overlap with other less serious conditions.

Which 13 Cancers Can The Blood Tests Detect?

Also read: Blood Test That Could Detect 50+ Cancers Closer To Approval As FDA Raises No Major Concerns About Its Accuracy

The trial will examine the tests for their ability to identify these 13 cancers:

1. Bowel cancer
2. Small bowel cancer
3. Stomach cancer
4. Oesophageal cancer
5. Pancreatic cancer
6. Liver cancer
7. Bile duct cancer
8. Gallbladder cancer
9. Ovarian cancer
10. Endometrial cancer
11. Kidney cancer
12. Bladder cancer
13. Prostate cancer

These cancers collectively equal approximately 35,000 deaths each year in England.

The study will evaluate three blood tests. One of them, called Enlighten, was developed by UK biotechnology company Proteotype Diagnostics. It looks for proteins in the blood that indicate the immune system may be responding to early signs of cancer.

Another test, Signatera, is already used by the NHS to monitor whether certain cancers have returned. It detects circulating tumour DNAor fragments of genetic material released by cancer cells into the bloodstream.

Early Detection Of Abdominal Cancers Is Important

Also read: Multicancer Blood Test Detects 17 Cancer In A Large Study: Can It Replace Mammograms & Colonoscopies?

Many abdominal cancers are diagnosed at advanced stages because their early symptoms can be easily mistaken for digestive problems or other common conditions.

Bloating, abdominal discomfort, changes in bowel habits, unexplained weight loss and loss of appetite can have several possible causes. This can make it difficult for patients and doctors to identify cancer early.

According to the trial announcement, around nine in 10 people diagnosed with stage 1 bowel cancer survive for at least five years, compared with approximately one in 10 people diagnosed at stage 4.

Professor Peter Johnson, NHS national clinical director for cancer and chair of the Office for Life Sciences Cancer Goal, said, “Detecting abdomen cancer early is notoriously difficult because the symptoms can easily be mistaken for other less serious conditions, but the NHS is determined to find a solution.”

He added, "We are at the start of revolution in cancer diagnosis, and this trial will help us to find out whether blood tests can help GPs get the right patients to the right tests sooner, supporting earlier diagnosis when treatment is most likely to be successful."

He said it was important to gather evidence about the new technologies and thanked those participating in the research.

Health Secretary Yvette Cooper also highlighted the potential benefits of earlier diagnosis.

"The earlier cancers are diagnosed, the more chance they can be successfully treated and lives can be saved," she said. "This world-first trial will establish whether simple blood tests can help GPs identify much sooner the patients who need urgent support."

The new STRIDE-RCT trial comes after the NHS-Galleri trial, which investigated whether a single blood test could detect multiple cancers before symptoms appeared.

That trial involved more than 142,000 people aged 50 to 77 across England. Participants were randomly assigned to receive either the Galleri blood test alongside usual NHS care or usual care alone.

The Galleri test looks for patterns in tumour DNA circulating in the blood that may signal the presence of cancer.

However, results published in September 2026 showed that the trial did not meet its primary objective of reducing the combined incidence of stage III and stage IV cancers across 12 cancer types. Researchers did observe fewer stage IV cancers, but said further follow-up was needed.